Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit

24 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment.

Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide.

Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice.

???? Highlights:

Global collaboration through the International Neuroendocrine Cancer Alliance (INCA)

Major new treatment approvals in 2025 (cabozantinib, belzutifan)

Promising data from recent and emerging clinical trials (COMPETE, PRRT advances)

A look toward the next wave of neuroendocrine cancer research

???? Recorded live at the 2025 INCA Summit in Sofia, Bulgaria
????‍⚕️ Guest: Dr. Jennifer Chan, President of NANETS
????️ Host: Lisa Yen, Neuroendocrine Cancer Foundation

#NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy
Categoria
Oncology
Commenta per primo questo video.

Prossimo